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Abstract: Polymeric hydrogels are common dosage forms designed for the topical administration
of antimicrobial drugs to treat vaginal infections. One of the major advantages of using chitosan in
these formulations is related to the intrinsic and broad antimicrobial activity exerted on bacteria and
fungi by this natural polymer. Most vaginal yeast infections are caused by the pathogenic fungus
Candida albicans. However, despite the anti-Candida activity towards and strains susceptibility to low
molecular weight chitosan being documented, no information is available regarding the antimicrobial
efficacy of mixed hydrogels in which chitosan is dispersed in a polymeric matrix. Therefore, the aim
of the study is to evaluate the anti-Candida activity against eight different albicans and non-albicans
strains of a mixed hydroxypropyl methylcellulose (HPMC)/chitosan hydrogel. Importantly, chitosan
was dispersed in HPMC matrix either assembled in nanoparticles or in a monomolecular state to
eventually correlate any variation in terms of rheological and mucoadhesive properties, as well
as anti-Candida activity, with the chitosan form. Hydrogels containing 1% w/w chitosan, either
as free polymer chain or assembled in nanoparticles, showed an improved mucoadhesiveness
and an anti-Candida effect against all tested albicans and non-albicans strains. Overall, the results
demonstrate the feasibility of preparing HPMC/CS mixed hydrogels intended for the prevention
and treatment of Candida infections after vaginal administration.
Keywords: mixed hydrogels; nanoparticles; Minimum Inhibitory Concentration (MIC); mucoadhesiveness;
Candida spp.
1. Introduction
Chitosan has been extensively exploited to develop topical formulations for ocular, mucosal or
skin applications thanks to its mucoadhesiveness and antimicrobial activity [1]. Aimed at prolonging
the residential time of the drug inside the vaginal cavity and to enhance the antibacterial or
antifungal activity of the delivered drug, several vaginal dosage forms containing chitosan have been
developed as films, tablets, inserts, hydrogels, and more recently, liposomes [2–7]. Among all these
formulations, hydrogels are still the most used, allowing easy and precise administration and being
largely versatile [8]. Moreover, hydrogels represent a non-expensive platform and they additionally
exert a moisturizing/lubricant effect on the mucosa [9]. Several mucoadhesive polymers have been
investigated for the preparation of hydrogels intended for vaginal applications. Among those, cellulose
derivatives, carboxypolymethylene and chitosan have been particularly investigated to improve the
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contact of the formulation with the vaginal mucosa and to reduce the dilution and clearance of the
hydrogels by the vaginal fluids [10].
For instance, Bonferoni et al. reported the preparation of a 3% chitosan-based hydrogel containing
lactic acid for the maintenance of the physiological vaginal pH [11]. In recent years, the field
of microbiocide drug delivery to the vaginal cavity has been developing a nanomedicine-based
approach using hydrogel embedded polymeric nanoparticles for the treatment or prevention
of vaginal infections [12,13]. Polymeric nanoparticles have been successfully incorporated in
chitosan-based hydrogels for vaginal administration in order to promote the drug penetration
inside the mucosa [14,15]. On the other side, chitosan nanoparticles were also dispersed in
polymeric hydrogels intended for different routes of drug administration [16,17]. The variety of
chitosan nanoparticle possible applications is closely related to their well-documented antibacterial
activity [18]. Many marketed hydrogels, intended for the treatment of vaginosis, contain metronidazole
and are effective against bacterial infections caused by vaginal bacteria and protozoa, such as
Gardnerella Vaginalis and Trichomonas Vaginalis. However, they are ineffective or display a low activity
against the common yeast co-infection by Candida spp. Indeed, a common therapeutic approach for
Candida spp. is topical treatment with azole antifungal drugs (e.g., clotrimazole), formulated as creams
(due to their low solubility in water). In this scenario, the antimycotic activity of chitosan has been
well documented, despite some controversial data being reported in regard to the major effect of
nanoparticles when compared to chitosan as free polymer [19,20]. As such, chitosan nanoparticles
could be employed to broaden the antimicrobial activity of drug-loaded vaginal hydrogel formulations
toward Candida spp. infections.
We propose here a formulation of a mixed hydrogel based on chitosan (in solution or
as nanoparticles) dispersed in a hydroxypropyl methylcellulose (HPMC) matrix loaded with
metronidazole (MTZ) (as an antimicrobial drug) for vaginal application. The main goal of the work
was to assess if chitosan could be successfully employed to improve the physico-chemical properties
of polymeric hydrogels loaded with metronidazole, while broadening their spectrum of antimicrobial
activity, including Candida co-infections. To this aim, we investigated the effect of chitosan, either
as nanoparticles or as free polymer, on the rheological, mucoadhesive properties and anti-Candida
activity of these hydrogel preparations.
2. Materials and Methods
2.1. Materials
Chitosan (CS) ChitoClear® (viscosity 9 Cp, Mw < 50 kDa, 90% degree of deacetylation, DD) was
kindly supplied by Primex (Siglufjordur, Iceland). Hydroxypropylmethyl cellulose (HPMC) K4M
Premium EP was supplied by Colorcon (Milan, Italy). Carboxypolymethylene polymer (Carbopol
974P) was kindly supplied by Lubrizol (IMCD, Barcelona, Spain). Sodium tripolyphosphate (TPP) and
mucin from porcine stomach type II were purchased from Sigma–Aldrich (Milan, Italy). Metronidazole
(MTZ) was purchased from ACEF (Fiorenzuola d’Arda, Italy). Ultrapure water (18.2 MΩ·cm) was
obtained by reverse osmosis using a Direct-Q® 3 UV (Millipore, Milan, Italy) apparatus.
2.2. Bacterial Strains and Culture Conditions
Eight strains of Candida spp., kindly furnished by Gamma Laboratory (Pesaro, Italy), were used
in this study: C. albicans 11/01, C. albicans 18/01, C. albicans 4940, C. albicans 360923, C. glabrata 104/1,
C. glabrata 104/22, C. glabrata 4955 and C. lusitaniae 360804. All the strains were isolated from urinary
human specimens (vaginal swabs) and identified by chromogenic Candida agar (CCA, Biolife, Milan,
Italy). The strains were routinely grown on Sabouraud Dextrose Agar (SDA) (Liofilchem, Roseto degli
Abruzzi, Italy) plates, incubated at 37◦ C for 24 h. Stock cultures were maintained at−80 ◦C in nutrient
broth (Oxoid, Milan, Italy) with 15% of glycerol.
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2.3. Methods
2.3.1. Preparation of Chitosan Nanoparticles (NPs)
Chitosan (CS) nanoparticles were obtained by a slightly modified gelation procedure, first reported
by Calvo et al. [21]. A 2% w/w stock dispersion of chitosan was prepared in acetate buffer, pH 4.5 [22],
and left stirring at room temperature for 24 hr. Nanoparticles were prepared at three chitosan
concentrations (0.1%, 0.5% and 1% w/w) and using different CS/TPP ratios. Briefly, 5 mL of
tripolyphosphate solution (containing the adequate amount of TPP) in acetate buffer, pH 4.5, was added
dropwise (at a rate of 200 µL/min) under stirring to 5 mL of CS dispersion in acetate buffer, pH 4.5,
at a double concentration as compared to that in the final preparation. CS nanoparticles were prepared
at different CS/TPP ratios according to CS concentrations. For 0.1% w/w CS final concentration,
nanoparticles were prepared at a CS/TPP weight ratios between 1:1 to 12:1, while for 0.5% and 1%
w/w CS concentration, nanoparticles were prepared at ratios ranging from 2:1 to 18:1.
2.3.2. Characterization of Chitosan Nanoparticles
CS nanoparticles were characterized by dynamic light scattering (DLS) and transmittance analysis.
The hydrodynamic diameters (nm) and the scattering intensity (counts, KCps) were measured by
DLS using a Zetasizer Nano S instrument (Malvern Instruments, Ltd., Malvern, UK). Briefly, 1 mL
of the sample was placed in a disposable cuvette and analysed at 25 ◦C, after 180 s of equilibration
time. The transmittance was measured at 660 nm using a UV-1800 spectrophotometer (Shimadzu,
Milan, Italy) at 25 ◦C. Transmittance of nanoparticles was reported as a relative percentage (%) with
the respect to that measured for the dispersion containing chitosan at the same concentration (0.1%,
0.5% and 1% w/w in acetate buffer, pH 4.5). The reported transmittance values are the average of five
consecutive measurements. All analyses were performed in triplicates.
2.3.3. Formulation of the Hydrogel Delivery System
Hydrogels were prepared by dispersing under stirring at 60 ◦C the adequate amount of HPMC
in acetate buffer pH 4.5 (for the control) and in CS or in CS nanoparticle dispersions (0.1% w/w,
0.5% w/w and 1% w/w in 200 mM acetate buffer, pH 4.5). Then, systems were cooled down under
stirring and left at room temperature for 2 days to assure the complete hydration of HPMC before
any further analysis. For the hydrogels containing nanoparticles, CS nanoparticle dispersions were
prepared immediately before the addition of HPMC at final CS concentrations in the hydrogel of 0.1%
w/w, 0.5% w/w and 1% w/w. The hydrogels were prepared using nanoparticles at certain CS/TPP
ratios, selected according to DLS and transmittance analysis results. The ratios were 6:1 and 12:1 for the
0.5% w/w and 1% w/w chitosan nanoparticles, and 6:1 and 2:1 for the 0.1% w/w nanoparticles. For the
preparation of the hydrogels loaded with metronidazole, the drug was dissolved in CS dispersions
(free polymer or nanoparticles) at a concentration of 0.75% w/w (with respect to the final weight of the
formulation), before adding HPMC.
2.3.4. Rheological Analysis
Rheological analyses were performed using a stress-controlled rotational rheometer (Kinexus
lab+, Malvern, UK) using a plate-cone geometry. The diameter of the cone was 40 cm and the angle
was 4◦. Samples, and the commercial formulation Zidoval®, used as a reference, were analysed by
stress sweep and frequency sweep tests at 37 ◦C. Stress sweep analysis was performed at a frequency of
1 Hz in the range 0.05–20 Pa. For the frequency sweep, an increasing frequency in the range 0.01–1 Hz
was applied to the samples at a constant stress (5 Pa). The measured rheological parameters were the
elastic modulus (G’), the viscous modulus (G”) and complex viscosity (Viscosity*). Analyses were
performed in triplicates.
Pharmaceutics 2018, 10, 23 4 of 15
2.3.5. Mucoadhesiveness Test
The mucoadhesiveness was evaluated in vitro by measuring the force required to detach the
hydrogel from the contact with a mucin tablet, as reported in the literature [23]. Tablets were obtained
by direct compression of mucin (400 mg) using a rotary tableting machine (Riva Piccola, Ronchi dei
Legionari, Italy) equipped with punches of 11.28 mm and by applying a compression force of 27 KN
(270 MPa) at 6 rpm. The obtained tablets had a hardness of 17 N and a thickness of 3.12 ± 0.05 mm.
Tablet hardness was measured through a hardness tester (TBH30, Erweka, Heusenstamm, Germany).
The thickness of the tablets was measured by a micrometer (103–137, Mitutoyo, Kawasaki, Japan).
The mucoadhesive test was performed using a tensile tester apparatus (5543, Instron, Pianezza, Italy)
equipped with a load cell of 5 N and a cylindrical probe with a diameter of 10 mm. The tablets were
attached through a cyanoacrylate glue to the lower end of the cylindrical probe. Then, prior to the
test, the tablets were hydrated by submersion in a 5% w/w of mucin dispersion in water for 5 min.
The excess hydration liquid was removed from the tablet surface by gentle blotting. For testing,
hydrogels were placed in glass vessels with diameters of 35 mm, and the probe was then lowered
until the tablet was in contact with the surface of the hydrogel and a force of 0.01 N was recorded.
The contact time was 2 min. After that, the cylindrical probe was moved up at a constant speed of
0.3 mm/s. The mucoadhesiveness of the hydrogels was expressed in terms of maximum mucoadhesive
force (Fmax; the force required for the detachment of the mucin tablet from the surface of the hydrogel),
displacement at the maximum force (Smax), total work (Workt) and work at the maximum force
(WorkIn). Fmax and Smax were calculated from the peak value of the force vs. the displacement
plot. Worktot and WorkIn were calculated from the total area and the partial area of the peak value
below the plot force vs displacement, respectively. The reported values are the mean ± SD of five
independent measurements.
2.3.6. Franz Diffusion Cell Release Study
The release study was performed using a Franz-cell diffusion apparatus (Start-up 6-Cell Manual
Test System, Hanson, Tulsa, OK, USA). Spectra/Por® 1 Dialysis Membranes (MWCO 6000/8000 Da,
pore size 0.45 µm, surface area 1 cm2) was placed between the donor and receptor chamber.
The receptor chamber was filled with 6.5 mL of 200 mM acetate buffer pH 4.5 at 37 ◦C under
constant stirring.
A quantity of 0.5 g of the analyzed hydrogels (HPMC 5.5%; HPMC 5.5%/CS 1%; HPMC 5.5% CS
NPs 1% 6:1 and HPMC 5.5% CS NPs 1% 12:1) and 0.75% MTZ solution in 200 mM acetate buffer pH 4.5
(as reference) were placed onto the membrane under occlusion conditions. Samples from the receptor
chamber (0.3 mL) were withdrawn at fixed time intervals (0, 15, 30, 60, 120, 240 min), and replaced with
an equal volume of fresh acetate buffer. The amount of the released metronidazole was quantified by
UV-spectroscopy (UV-1800 Shimadzu) through a calibration curve (λ = 277 nm, y = 0.01419x − 0.0071).
The results were expressed as the mean ± SD cumulative release of metronidazole (%), with respect to
the nominal amount of drug loaded in the formulation. Analyses were performed in triplicate.
2.3.7. Antimicrobial Activity of the Hydrogels
The antimicrobial activity of the different hydrogels and the relative controls (chitosan dispersions)
was tested using the agar well diffusion method (AWDM), in accordance with Campana et al. with
slight modifications [24]. Briefly, several colonies were drawn from each plate of Candida spp., added to
30 mL of Triptone Soy Broth (TSB, Oxoid) and incubated at 37 ◦C for 24 h. At this point, each pathogen
culture (about 107 CFU mL−1) was streaked on the surface of 25 mL of SDA plates and then kept at
room temperature under flow cabinet for 20 min. Wells of 6 mm in diameter were made on the agar
with sterile stainless-steel cylinders and 80 µL of each tested CS dispersion, and CS/HPMC hydrogels
were pipetted into the wells. Fluconazole (Sigma) solutions (25 and 50 µg/mL) were also tested as
controls. After 24 h of incubation at 37 ◦C, the diameter of the inhibition zone around each well was
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measured, and the antimicrobial activity was expressed as the mean ± standard deviation of the
inhibition diameters produced by each sample. All the experiments were performed in duplicate.
2.3.8. Statistical Analyses
Statistical analyses were performed with MINITAB® Release 14.1 (Minitab Inc., Coventry, UK,
1972–2003) software. All statistical comparisons were made through a one-way ANOVA test with p
values < 0.05 considered statistically significant.
3. Results and Discussions
3.1. Characterization of Chitosan Nanoparticles
DLS measurements and transmittance analyses were performed for all the formulations,
to investigate the effect of the chitosan concentration (%) and CS/TPP ratio on the formation and size
of the obtained nanoparticles in acetate buffer, pH 4.5 (Figure 1). By comparing the hydrodynamic
diameters calculated for the nanoparticles prepared at different CS concentrations, it became clear
that the percentage of CS markedly influences the nanoparticle size. For nanoparticles obtained
with 0.1% w/w of chitosan, the hydrodynamic diameter was found to be in the range of 85–95 nm,
while sizes of approximately 300 and 900 nm were detected for particles prepared with 0.5% w/w
and 1% w/w of chitosan, respectively. The increase in size as a function of the CS concentration is
well documented in the literature for nanoparticles prepared by ionic gelation [25,26]. On the contrary,
the effect of the CS/TPP ratio is less straightforward and it required a more detailed analysis. Indeed,
the size evolution nanoparticles as a function of the CS/TPP ratio displayed a typical profile at any
tested concentration. Nanoparticle size remained constant in a specific range of CS /TPP ratios in
a chitosan concentration dependent manner. Specifically, the range of CS/TPP ratios in which the size
of the nanoparticles was similar was found to be between 10:1 and 16:1 for 0.5% w/w and 1% w/w CS
concentrations and between 4:1 and 10:1 for 0.1% w/w CS concentration. For ratios above this range,
the formation of nanoparticles generally did not occur, while for lower ratios, a progressive increase
in size was observed, leading to flocculation and CS precipitation at a ratio of 2:1 for 0.5% w/w and
1% w/w of chitosan and 1:1 for 0.1% w/w of chitosan. To evaluate the relevance of these two specific
parameters—the CS/TPP ratio and chitosan concentration (%)—on nanoparticle size, a two-way
variance analysis was performed. For this purpose, 18:1, 16:1 and 14:1 ratios were not included in the
analysis because they did not produce any nanoparticles. In addition, the 2:1 ratio was also excluded
since large aggregates were observed and they could affect the statistical analysis, leading to false
positive results. All the considered parameters (CS concentration, CS/TPP ratio and the interaction
term) were statistically significant (p value < 0.001 for CS concentration and CS/TPP ratio and 0.005
for the interaction term), but the CS concentration had a higher impact on the size (F value for CS
concentration was at least 75 times higher than for the other two parameters). The effect of all the
parameters considered can be easily displayed through the main effect and interaction plot (S1 and
S2). A rise in CS concentration resulted in an increase of the nanoparticle size, while an opposite and
limited effect was observed for CS/TPP ratios (main effect plot, Figure S1). Interestingly, the effect of
CS/TPP ratio was much more pronounced at the highest CS concentration (interaction plot, Figure S2).
Counts (Kpcs) were also recorded through DLS, as they represent a measure of the scattered light
intensity received by the detector, which depends on the nature, size and concentration of the disperse
system. At higher CS/TPP ratios (above 10:1 for nanoparticles containing 0.5% w/w and 1% w/w
of chitosan and above 4:1 for systems containing 0.1% w/w chitosan), counts were constant, but at
lower ratios, they progressively increased. Considering that the size of nanoparticles did not increase
markedly over the different ratios (except for 2:1), it can be speculated that the increase in counts could
be related to the presence of a higher number of nanoparticles at lower CS/TPP ratios. To validate this
hypothesis, the transmittance was also measured. It can be observed that the increase in counts was
accompanied by a decrease in the measured transmittance value of the samples. The variation in the
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optical properties of the samples at different CS/TPP ratios and chitosan concentrations (%) can be
also seen by a visual observation of the samples. Indeed, systems at 0.1% w/w CS concentration are
transparent (except for the 2:1), while at higher concentrations of chitosan (0.5% w/w and 1% w/w),
as the CS/TPP ratio lowers, a gradual increase in the opacity of the samples can be observed (Figure 2).Pharmaceutics 2018, 10, 23 6 of 15 
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mean ± SD of three independent measurements.
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pH 5.5, to evaluate the effect of pH on nanoparticles size. Results from this investigation can be found 
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that is required to produce hydrogels in acetate buffer, pH 4.5, showing a consistency comparable to 
that of a jellified commercial formulation intended for vaginal administration. For comparison, the 
marketed hydrogel known as Zidoval® was selected. Zidoval® is formulated using a 
carboxypolymethylene polymer (Carbopol 974P), that displays carboxylic groups in the backbone. 
The polymeric dispersion thickens and forms a hydrogel after neutralization with inorganic (e.g., 
sodium hydroxide) or organic (e.g., triethanolamine) bases. At this pH value, chitosan precipitation 
occurs, therefore, carboxypolymethylene was not suitable for the preparation of mixed chitosan 
hydrogels. HPMC was chosen since the formation of the hydrogels is independent from the pH, due 
to the absence of ionisable groups. 
Hydrogel formulations prepared at 5.5% w/w HPMC concentration (control, CS and CS NPs 
0.1% w/w, 0.5% w/w and 1% w/w) and Zidoval® were compared by looking at the rheological 
parameter “complex viscosity” (viscosity*). Viscosity* is a measure of the viscosity of a semisolid 
system obtained through an oscillatory stress sweep test (Figure 3A). Only two CS/TPP ratios (6:1 
and 2:1 for 0.1% w/w CS and 6:1 and 12:1 for 0.5% w/w and 1% w/w CS) were selected for the 
preparation of HPMC/CS NP hydrogels, in accordance with DLS and transmittance results. 
Hydrogels at the two CS/TPP ratios had a similar appearance to that of nanoparticle dispersions. 
Specifically, the hydrogels prepared at lower CS/TPP ratios were more opaque with respect to those 
prepared at the same concentration but at higher CS/TPP ratios (Figure S5). 
Figure 2. Image of the prepared chitosan nanoparticle dispersions in 200 mM acetate buffer pH 4.5 at
the three different concentrations (0.1% (A), 0.5% (B) and 1% (C); w/w).
In addition to pH 4.5, CS nanoparticles in 200 mM acetate buffer were also prepared at pH 5 and
pH 5.5, to evaluate the effect of pH on nanoparticles size. Results from this investigation can be found
in the supplementary materials (Figures S3 and S4).
3.2. Rheological Analysis of HPMC/CS Hydrogels
A preliminary screening was performed, in order to investigate the HPMC concentration (%) that
is required to produce hydrogels in acetate buffer, pH 4.5, showing a consistency comparable to that of
a jellified commercial formulation intended for vaginal administration. For comparison, the marketed
hydrogel known as Zidoval® was selected. Zidoval® is formulated using a carboxypolymethylene
polymer (Carbopol 974P), that displays carboxylic groups in the backbone. The polymeric dispersion
thickens and forms a hydrogel after neutralization with inorganic (e.g., sodium hydroxide) or
organic (e.g., triethanolamine) bases. At this pH value, chitosan precipitation occurs, therefore,
carboxypolymethylene was not suitable for the preparation of mixed chitosan hydrogels. HPMC was
chosen since the formation of the hydrogels is independent from the pH, due to the absence of
ionisable groups.
Hydrogel formulations prepared at 5.5% w/w HPMC concentration (control, CS and CS NPs
0.1% w/w, 0.5% w/w and 1% w/w) and Zidoval® were compared by looking at the rheological
parameter “complex viscosity” (viscosity*). Viscosity* is a measure of the viscosity of a semisolid
system obtained through an oscillatory stress sweep test (Figure 3A). Only two CS/TPP ratios (6:1 and
2:1 for 0.1% w/w CS and 6:1 and 12:1 for 0.5% w/w and 1% w/w CS) were selected for the preparation
of HPMC/CS NP hydrogels, in accordance with DLS and transmittance results. Hydrogels at the two
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CS/TPP ratios had a similar appearance to that of nanoparticle dispersions. Specifically, the hydrogels
prepared at lower CS/TPP ratios were more opaque with respect to those prepared at the same
concentration but at higher CS/TPP ratios (Figure S5).Pharmaceutics 2018, 10, 23 8 of 15 
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Figure 3. Rheological results of stress sweep (A) and frequency sweep (B) tests obtained from
hydroxypropyl methylcellulose (HPMC)/Chitosan NPs hydrogels at 37 ◦C.
In regard to the rheological results, 5.5% w/w HPMC hydrogel showed a viscosity* of 45 ± 3 Pa*s
at 37 ◦C. The presence of chitosan, both as free polymer or as nanoparticles, increased the strength
of the HPMC/chitosan mixed hydrogel. Particularly, a value of viscosity* comparable to Zidoval®
(75–80 Pa*s) was obtained at a concentration of 1% w/w chitosan, both as free polymer or nanoparticles
(Figures 3A and S6).
On the other side, the presence of chitosan did not markedly affect the viscoelastic properties of
HPMC hydrogels, as we can see from the trend of the elastic (G’) or viscous (G”) moduli (Figure 3B
and Figure S6. However, what these analyses have pointed out is the different rheological behaviour of
Zidoval® with respect to HPMC hydrogels. Indeed, Zidoval® can be considered a true gelling system
from a rheological point of view. This is because the elastic modulus (G’) is higher than the viscous
modulus (G”) at any tested frequency (Figure 3B). In contrast, the prepared hydrogels cannot be
defined as a gel from a rheological point of view, but they can be considered as concentrated polymer
dispersions. In this case, the rheological moduli (G’ and G”) are dependent on the applied frequency
and show a frequency cross point. At frequencies below this point, the viscous modulus is higher
than the elastic modulus and, consequently, they behave as a liquid dispersion. On the other side,
at frequencies above the cross point, the elastic modulus is higher than the viscous modulus and
they behave as weak gels. As such, the negligible effect of CS on the viscoelastic properties of 5.5%
HPMC hydrogels can be evaluated in terms of cross points of the rheological moduli (G’ and G”),
which were found to be in the range 3–6 Hz for all the prepared systems (HPMC, CS/HPMC and CS
NPs/HPMC hydrogels).
3.3. Mucoadhesiveness Test
HPMC hydrogels containing 0.5% and 1% w/w of chitosan, both as free polymer and as nanoparticles,
were analysed in term of their mucoadhesive properties. As shown in Table 1, a statistically significant
increase (one-way ANOVA followed by Dunnett’s multiple comparisons test) in the mucoadhesiveness
compared to the control (HPMC 5.5% w/w in acetate buffer 200 mM pH 4.5) was only observed for the
hydrogels containing 1% w/w of chitosan (both as free polymer or as nanoparticles) by considering the
maximum force (N) of detachment of the hydrated mucin tablet from the hydrogel surface (p < 0.007).
A slight increase in the “total work” (mJ) and the “work at the maximum force” (mJ) were observed
for the 1% w/w chitosan hydrogels, but in this case, such differences were not statistically significant
with respect to the control. The results confirmed the mucoadhesive properties of HPMC. Indeed,
at the concentration used, the mucoadhesion of the hydrogels is controlled by HPMC, while chitosan
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(as free polymer or nanoparticles) exerts a certain effect only at a concentration of 1% w/w. The effect
on mucoadhesion of lower concentrations of chitosan (as 0.5% w/w) can be hindered by the presence
of a larger amount of the mucoadhesive polymer, HPMC (5.5% w/w). This assumption is supported
by the fact that in hydrogels formed by polymers with less mucoadhesive properties than HPMC
(e.g., Poloxamer 407) [27], there is an effect of the presence of chitosan on mucoadhesion at a lower
concentration [23].
Table 1. Mucoadhesiveness parameters (Fmax; Smax; Worktot, Workin) calculated from the in vitro
mucoadhesiveness test performed on the prepared HPMC 5.5% (w/w) hydrogels in presence of 0.5%
(w/w) and 1% (w/w) chitosan, both as free polymer and as nanoparticles. The reported values are the
mean ± SD of five replicates.
Formulations Fmax (N) SMax (mm) Worktot(mJ) Workin (mJ)
HPMC 0.017 ± 0.001 1.615 ± 1.107 0.057 ± 0.009 0.017 ± 0.003
HPMC + CS 0.5% 0.018 ± 0.001 1.176 ± 0.183 0.060 ± 0.020 0.019 ± 0.003
HPMC + CS 1% 0.021 ± 0.002 * 1.224 ± 0.231 0.064 ± 0.025 0.020 ± 0.014
HPMC + CS NPs 1% 12:1 0.022 ± 0.002 * 1.056 ± 0.232 0.065 ± 0.020 0.019 ± 0.004
HPMC + CS NPs 1% 6:1 0.023 ± 0.002 * 0.888 ± 0.267 0.060 ± 0.022 0.019 ± 0.018
HPMC + CS NPs 0.5% 12:1 0.018 ± 0.002 1.389 ± 0.182 0.058 ± 0.027 0.018 ± 0.006
HPMC + CS NPs 0.5% 6:1 0.020 ± 0.003 0.899 ± 0.250 0.051 ± 0.018 0.017 ± 0.004
* hydrogels formulation statistically different (p < 0.05) from the control (HPMC 5.5%).
3.4. Franz diffusion Cell In Vitro Release Study
Franz-cell diffusion studies were performed to investigate the influence of the presence of 1% w/w
chitosan as free polymer or nanoparticles in the release of metronidazole from 5.5% w/w HPMC
hydrogels. Only hydrogels containing 1% w/w of CS were analyzed, since they showed an effect on
the mucoadhesive properties of the system. The calculated metronidazole cumulative release (%) over
time from HPMC hydrogels and CS solution (as comparison) is shown in Figure 4. All the hydrogels
displayed a similar release profile, independently of whether chitosan was present as a free polymer
or as nanoparticles. This result is in accordance with the rheological analyses, which denoted the
non-marked effect of the 1% w/w chitosan (as both free polymer and nanoparticles) on the viscoelastic
properties of 5.5% w/w HPMC hydrogels. The release of metronidazole from these systems was found
to be quite slow at the tested conditions (around 25–30% after 240 min) [28], while 100% release was
achieved when the drug was dissolved in 200 mM acetate buffer.
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3.5. Antimicrobial Activity of HPMC/CS Hydrogels
Several studies have been conducted to investigate the effect of chitosan or chitosan nanoparticles
on fungal growth [29–31]. The obtained results have showed a marked antifungal activity exerted
by chitosan against different fungal strains, including pathogenic species for humans as Candida
spp. [20,32,33]. Fungicidal activity was demonstrated for chitosan, possibly due to membrane damage
as a consequence of the interaction between protonated amino groups with negatively-charged cell
surface proteins [34]. Despite the conspicuous number of experimental works, there is still a debate
regarding the greater efficacy and broader activity of nanoparticles with respect to chitosan as
free polymer.
Candida albicans is the main fungus responsible for vaginal yeast infections, although less
frequently co-infection with other non-albicans Candida species (Candida glabrata, Candida lusitaniae)
can occur [35]. The infections by species other than Candida albicans are reported to be more resistant to
common antimycotic treatments (azole drugs; e.g., fluconazole) and responsible for the recurrence
of the infection [36,37]. In this work, a panel of eight strains of Candida spp. (four albicans and four
non-albicans) was tested, in order to investigate the anti-Candida activity of 1% chitosan as free polymer
and nanoparticles, formulated both as aqueous dispersions or dispersed in a 5.5% HPMC hydrogel.
Initially, the susceptibility of the selected Candida spp. strains to fluconazole, as an antifungal
azole drug model, was studied. Most of the strains were resistant to fluconazole at the two tested
concentrations (25 µg/mL and 50 µg/mL), with the exception of C. albicans 360923, which showed
inhibition diameters of 20 ± 1.25 and 28 ± 0.75 mm for fluconazole 25 µg/mL and 50 µg/mL,
respectively (Table S1), comparable to those already reported in the literature [38].
In the present study, MIC values for chitosan were not determined since its efficacy against
Candida spp. is well-known from the literature [32,39]. The tested chitosan concentration (1% w/w)
was selected as the highest that produced nanoparticles at the investigated experimental conditions.
The aim was to compare the anti-Candida activity of CS (as both free polymer and nanoparticles) when
dispersed into HPMC hydrogels with that of CS dispersions prepared at the same concentrations.
The results obtained from the agar well diffusion method are summarized in Table 2. The 1% w/w
CS dispersion in 200 mM acetate buffer, pH 4.5, displayed good activity against all the tested Candida
spp. strains, with inhibition growth diameters ranging from 12 ± 0.78 mm for C. albicans 18/01,
to 13 ± 0.27 mm for C. albicans 4940 and C. glabrata 4955. One-percent CS nanoparticles in 200 mM
acetate buffer, pH 4.5, have, instead, a different profile of activity. Indeed, 1% CS NPs were ineffective
against all the tested C. albicans strains, while showing a comparable inhibition growth effect to 1% w/w
CS dispersion (as free polymer), against the tested non-albicans strains. By considering nanoparticles
at different CS/TPP ratios, the activity of nanoparticles prepared at the ratio 12:1 was slightly higher
than those prepared at 6:1 for all tested non-albicans strains. This could be related, as already reported
in the literature, to the smaller particle size obtained for the systems prepared using a 6:1 CS/TPP ratio
when compared to those obtained at 12:1 ratio [19].
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Table 2. Antimicrobial activity of HPMC/CS hydrogels and relative controls (CS dispersions), assessed by the agar well diffusion method (AWDM) against eight
strains of Candida spp. obtained from vaginal swabs. The data represent the growth inhibition diameter (in mm) of each tested sample. Values are reported as the
mean ± SD of two replicates.
Inhibition Growth Diameter (mm)
Formulations
Albicans Strains Non-Albicans Strains
C. albicans 11/01 C. albicans 18/01 C. albicans 4940 C. albicans 360923 C. glabrat 104/1 C. glabrata 104/22 C. glabrata 49/55 C. lusitaniae 360804
CS 1% 12 ± 0.6 12 ± 0.8 13 ± 0.3 13 ± 0.2 12 ± 0.6 13 ± 0.2 13 ± 0.3 13 ± 0.2
CS NPs 1% 6:1 0 0 0 0 9 ± 0.2 9 ± 0.3 9 ± 0.3 10 ± 0.1
CS NPs 1% 12:1 0 0 0 0 12 ± 0.8 11 ± 0.6 12 ± 0.7 13 ± 0.2
HPMC 0 0 0 0 0 0 0 0
HPMC CS 1% 12 ± 0.5 12 ± 0.6 12 ± 0.4 11 ± 0.3 12 ± 0.4 11 ± 0.4 12 ± 0.3 11 ± 0.2
HPMC + CS NPs 1% 6:1 9 ± 0.2 8 ± 0.3 8 ± 0.2 11 ± 0.6 9 ± 0.3 9 ± 0.2 10 ± 0.5 9 ± 0.1
HPMC + CS NPs 1% 12:1 9 ± 0.2 11 ± 0.3 8 ± 0.2 9 ± 0.2 10 ± 0.8 9 ± 0.2 12 ± 0.6 15 ± 0.6
MTZ 0.75% 0 0 0 0 0 0 0 0
CS 1% MTZ 0.75% 12 ± 0.6 12 ± 0.8 13 ± 0.2 12 ± 0.8 13 ± 0.3 14 ± 0.3 14 ± 0.3 13 ± 0.2
CS NPs 1% 6:1 + MTZ 0.75% 0 0 0 0 9 ± 0.4 9 ± 0.4 9 ± 0.2 11 ± 0.2
CS NPs 1% 12:1 + MTZ 0.75% 0 0 0 0 12 ± 0.6 11 ± 0.5 12 ± 0.6 12 ± 0.7
HPMC + MTZ 0.75% 0 0 0 0 0 0 0 0
HPMC+CS 1% + MTZ 0.75% 13 ± 0.5 12 ± 0.5 11 ± 0.4 11 ± 0.2 13 ± 0.4 10 ± 0.4 11 ± 0.2 11 ± 0.2
HPMC + CS NPs 1% 6:1 + MTZ 0.75% 9 ± 0.2 9 ± 0.3 8 ± 0.2 9 ± 0.2 9 ± 0.2 9 ± 0.2 9 ± 0.2 11 ± 0.3
HPMC + CS NPs 1% 12:1 + MTZ 0.75% 12 ± 0.7 11 ± 0.6 12 ± 1.0 10 ± 0.4 10 ± 0.6 11 ± 0.5 12 ± 1.0 11 ± 0.6
Pharmaceutics 2018, 10, 23 12 of 15
In regard to the HPMC-based hydrogel formulation containing 1% chitosan as free polymer,
it was able to inhibit the growth of all tested Candida spp. with a variable degree of activity. Generally,
a slightly lower effect with respect to 1% w/w CS dispersion was observed, which could be related to
the slow diffusion capacity of CS in the hydrogel matrix if compared to a buffer solution. Interestingly,
hydrogels formulated with 1% w/w CS NPs, in contrast to 1% w/w CS NPs as a dispersion (which
was active only on non-albicans species), showed activity against all tested albicans and non-albicans
strains. Indeed, the greatest zone of inhibition was obtained with the hydrogel HPMC/CSNPs 12:1
against C. lusitaniae 360804 (15 ± 0.57 mm), followed by C. glabrata 4955 (12 ± 0.57 mm) and C. albicans
18/1 (11 ± 0.25 mm), whilst lower zones of growth inhibition were observed with the hydrogel
HPMC-CSNPs 6:1 (from 11 ± 0.57 mm for C. albicans 360923 to 8 ± 0.25 mm for C. albicans 4940).
Despite CS NPs/HPMC hydrogels being active against all tested strains, a higher susceptibility was
observed for non-albicans species and NPs prepared at 12:1 CS/TPP ratio. The different susceptibility
among the tested strains could be explained by considering the structural differences of the cell wall
among Candida spp. The cell wall of C. albicans, indeed, has more chitin and less adhesin molecules
than that of C. glabrata [29,40]. Thus, the anti-Candida activity of chitosan was more pronounced
against the strains with more chitin in the cell wall. Moreover, the presence of HPMC could facilitate
the penetration of chitosan in the cell wall of the strain (i.d. C. albicans), justifying the broader range of
the activity of the hydrogels containing chitosan, in comparison to CS dispersions, when analysed at
the same concentration. Moreover, as for CS dispersions, the higher activity of the hydrogels prepared
with CS NPs at 12:1 could be related to the smaller size.
Since common antifungal drugs are insoluble or slightly soluble in water, their formulation
as hydrogels, using therapeutically-active concentrations of the drugs, is not feasible. Indeed,
they are commercialized as cream for vaginal administration, instead of hydrogels. The formulation
as hydrogels could be still possible using ethanol as a co-solvent to promote the solubilization
of the drug. However, ethanol can act as a non-solvent for chitosan, thereby destabilizing the
formulation [41]. For these reasons, we decided to prepare CS/HPMC hydrogels loaded with
metronidazole, an antiprotozoal drug, approved for the treatment of bacterial vaginosis as a 0.75% w/w
hydrogel. Metronidazole does not have intrinsic anti-Candida activity, but hydrogels containing
metronidazole are available on the market for the treatment of bacterial vaginosis. A formulation of
hydrogels loaded with metronidazole in the presence of chitosan could be a strategy to formulate
a jellified system with improved antimicrobial activity against both vaginal bacteria and Candida
spp. As such, metronidazole has been already formulated in other chitosan-based dosage forms,
in order to address a combined effect on bacterial and yeast infections of the vaginal mucosa [5].
Metronidazole was not encapsulated inside CS nanoparticles, but it was solubilized inside the
polymeric matrix, in order to formulate a hydrogel at the same drug concentration (0.75% w/w) as the
commercial formulations. Metronidazole solution 0.75% (in 200 mM acetate buffer, pH 4.5) and 0.75%
metronidazole HPMC hydrogel, tested as controls, did not show any anti-Candida activity against all
tested strains. Moreover, the addition of 0.75% to 1% CS dispersion or 1% CS/HPMC hydrogels (as free
polymer or nanoparticles) did not determine any increase in the antimicrobial activity against all the
tested Candida spp. strains. These results confirmed that the presence of metronidazole did not exert
any influence on the intrinsic anti-Candida effect of chitosan when both formulated as nanoparticles
and dispersed into a polymeric hydrogel.
4. Conclusions
HPMC based hydrogels in the presence of different concentrations (0.1%, 0.5% and 1% w/w) of low
molecular weight chitosan, either as free polymer or as nanoparticles, were successfully formulated at
pH 4.5 and characterized in terms of rheological and mucoadhesive properties. Hydrogels containing
1% w/w chitosan showed a suitable viscosity (comparable to that of a commercial formulation) and
an improved mucoadhesiveness in comparison to the control. These features make these hydrogels
suitable for the vaginal administration and have been proposed here as a strategy to treat vaginal
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co-infections. Indeed, when incorporated in a 5.5% w/w HPMC matrix in mixed hydrogels, chitosan
maintained its wide spectrum of anti-Candida activity against both albicans and non-albicans strains.
In particular, no large differences in terms of intrinsic activity, evaluated from the inhibition growth
diameter measured by agar well diffusion method, were observed between the hydrogels prepared
with chitosan as free polymer or as nanoparticles. However, few differences were found in regard
to the susceptibility of the different strains, with an observed higher effect on non-albicans versus
albicans species.
Overall, this study reports, for the first time, the anti-Candida activity of chitosan as free polymer
or nanoparticles, dispersed in a polymeric matrix forming a hydrogel. Moreover, the results suggest
the possibility of using mixed hydrogels, composed of a HPMC matrix in which chitosan is dispersed,
for the treatment or prevention of vaginal Candida co-infections. In this regard, the presence of chitosan
can broaden the activity toward Candida spp. of hydrogel formulations containing the antimicrobial
drug, metronidazole, commonly employed for the treatment of vaginal infections.
Supplementary Materials: The following are available online at www.mdpi.com/1999-4923/10/1/23/s1,
Figure S1: “Main effect” plot relative to the factors (CS % and CS/TPP ratio) influencing the size of nanoparticles,
Figure S2: “Interactions plot” between the factors (CS% and CS/TPP ratio) influencing the size of nanoparticles,
Figure S3: Hydrodynamic diameter (nm), counts (Kcps) and transmittance (%) of nanoparticles at different CS
concentrations (0.1%, 0.5% and 1%; w/w) and different CST/TPP ratio prepared in acetate buffer pH 5, Figure S4:
Hydrodynamic diameter (nm), counts (Kcps) and transmittance (%) of nanoparticles at different CS concentrations
(0.1%, 0.5% and 1%; w/w) and different CST/TPP ratios prepared in acetate buffer pH 5.5, Figure S5: Image of the
prepared HPMC/CS mixed hydrogels in 200 mM acetate buffer pH 4.5. From left to right: 5.5% HPMC (control);
5.5% HPMC/1%CS; 5.5% HPMC/1%CS NPs 12:1; 5.5% HPMC/1%CS NPs 6:1, Figure S6: Stress sweep (A) and
frequency sweep (B) results obtained from HPMC/CS mixed hydrogels at 37◦C. CS was dispersed into HPMC as
free polymer, Table S1: Growth inhibition diameter (in mm) of Fluconazole (25 and 50 µg/mL) tested against the
different Candida spp. strains. Values are reported as the mean ± SD of two replicates.
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